Data protection Impressum

Healthcare

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (January 2025)

28 January 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

EBAMed has secured an additional EUR 1.6 million in Series A funding, bringing the total raised to EUR 16 million. This new investment, contributed by CDP Venture Capital and the European Union, supports the development of EBAMed’s groundbreaking CardioKit system for non-invasive treatment of heart arrhythmias using Proton Therapy.

Geneva medtech EBAMed completes financing round with EUR 16 million

27 January 2025

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.

BrainScape Medical makes strides in long-term brain monitoring

21 January 2025

Start-up Aspivix has raised EUR 1.95 million through a crowdfunding campaign to advance the commercialization of its innovative gynecological device, Carevix™. The campaign, hosted on the Capital Cell platform, aims to reach a target of EUR 2.15 million by 15 March 2025.

Medtech Aspivix secures EUR 1.95 million in crowdfunding

20 January 2025

Fribourg-based digital health start-up Neuria, a spin-off from the University of Fribourg, is set to launch its patented brain recalibration platform in Switzerland and the US.

Fribourg’s Neuria prepares to launch its brain recalibration platform

13 January 2025

Actival, a medtech spin-off from CSEM, has received CHF 150,000 from Venture Kick to launch its Active Aligners, a groundbreaking solution addressing the hygiene challenges of traditional clear aligners.

Neuchâtel’s Actival receives Venture Kick support to launch its innovative dental aligners

8 January 2025

Vanarix, a Biopôle-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its bioengineered cartilage mini-implants, Cartibeads.

Vanarix secures FDA Orphan Drug designation for its Cartibeads

7 January 2025

Vandria, a Lausanne-based biotech pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318, marking a critical step toward addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Vandria begins clinical trials for Alzheimer’s drug VNA-318

7 January 2025

1 2 3 4 5 6 7 8 9 … 18